Publications by authors named "Sheba Ziyenge"
Article Synopsis
- - The study investigates the effectiveness of convalescent plasma (CP) therapy for COVID-19 by evaluating different immunoassays and their ability to predict neutralizing antibody levels in CP donations.
- - Researchers tested three immunoassays (EUROimmun, Ortho, Roche), a pseudotype-based assay, and two others assessing ACE2 binding to gauge their efficacy in determining antibody strength across 113 CP samples.
- - All assays effectively identified high-titer donations, but their ability to predict neutralizing antibody levels varied, with the pseudotype assay showing the best correlation (0.61), suggesting they could be used for selecting CP donations.
Background: Convalescent plasma containing neutralizing antibody to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is under investigation for coronavirus disease 2019 (COVID-19) treatment. We report diverse virological characteristics of UK intensive care patients enrolled in the Immunoglobulin Domain of the REMAP-CAP randomized controlled trial that potentially influence treatment outcomes.
Methods: SARS-CoV-2 RNA in nasopharyngeal swabs collected pretreatment was quantified by PCR.